NASDAQ · DMAAR
Drugs Made In America Acquisition Corp. Rights
Financial Services · Shell Companies
$0.13
Up+$0.00 (+2.00%)
Updated Oct 12, 2026, 3:39 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.98M
- P/E ratio
- 41.6
- Dividend yield
- 0.00%
- 52-week range
- $0.04 – $0.21
- Volume
- 103
- Avg. volume
- 87.91K
Price performance · DMAAR
DMAAR price history
1M range · 14 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
DMAAR closed at $0.13 after 14 trading sessions, up 12.83% for the selected period.
- Last close
- $0.13
- Period change
- +12.83%
- Period low
- $0.11
- Period high
- $0.13
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $0.1275 | $0.1275 | $0.1275 | $0.1275 | 103 |
| Oct 8, 2026 | $0.11 | $0.1267 | $0.11 | $0.125 | 10.53K |
| Oct 7, 2026 | $0.1249 | $0.1275 | $0.1006 | $0.1275 | 722.39 |
| Oct 6, 2026 | $0.11 | $0.1277 | $0.11 | $0.1244 | 21.96K |
| Oct 2, 2026 | $0.1275 | $0.1275 | $0.1275 | $0.1275 | 8K |
| Oct 1, 2026 | $0.1249 | $0.1264 | $0.11 | $0.1264 | 2.15K |
| Sep 28, 2026 | $0.1132 | $0.1264 | $0.1131 | $0.1249 | 785.35 |
| Sep 25, 2026 | $0.1051 | $0.1264 | $0.10 | $0.125 | 30.67K |
| Sep 24, 2026 | $0.1052 | $0.1264 | $0.1051 | $0.1263 | 21.25K |
| Sep 23, 2026 | $0.1262 | $0.1262 | $0.105 | $0.1262 | 471 |
| Sep 18, 2026 | $0.1071 | $0.1264 | $0.1071 | $0.1264 | 386.2 |
| Sep 17, 2026 | $0.1273 | $0.1273 | $0.1072 | $0.1264 | 538 |
| Sep 16, 2026 | $0.1275 | $0.1275 | $0.11 | $0.1249 | 67.98K |
| Sep 15, 2026 | $0.111 | $0.1274 | $0.11 | $0.113 | 45.61K |
Latest DMAAR news
The latest Smart Investors Daily articles mentioning DMAAR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DMAAR research
Overview
Company profile and research snapshot.
Company profile
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
